Trial
NCT01374451
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Islet Cell Tumor
Intervention
Everolimus
Why stopped
The study was stopped for not meeting the primary endpoint for PFS.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-20